Brucellosis still poses a challenge in many areas of the world to this day even after considerable studying and interventions have taken place. Our firm is recognized for excellence in vaccine development, brucellosis therapy and other related services. We specialize in building efficient solutions for pharmaceutical companies that are looking to expand their global presence.
Introduction to Brucellosis
Zoonotic brucellosis is an infectious disease caused by a Brucella bacteria which infects livestock including cattle, sheep, goat, and pigs. The animals' primary non-specific symptoms are constantly feeling unwell, persistent fever, and joint and muscle aches. These side-effects contribute to manic depression, chronic fatigue and other life- hindering infectious diseases.
Brucella bacteria are able to escape detection and enhance the severity of the disease by causing intracellular infection which is a more robust disease modulation process. The bacteria are able to reproduce and expand which further contributes to the relapsing and chronic nature of Brucellosis.
Fig. 1 Timeline of introduction of blood culture methods for isolation of Brucella organisms. (Yagupsky P., et al., 2019)
Vaccine Development for Brucellosis
The search for an ideal brucellosis vaccine has been an ongoing pursuit, as currently available options exhibit various drawbacks. The Brucella abortus S19 and Brucella melitensis Rev.1 vaccines, on the other hand, exhibit good protection but suffer from some defects such as residual virulence, interference with serodiagnosis and concern in people. Another vaccine named as Brucella abortus RB51 has been revealed to be of variable efficacy and exhibits resistance for some of the important antibiotics meant for the treatment of the disease. To overcome these shortcomings, however, scientists have investigated new options in immunogenetic engineering.
Table 1 Summary of Brucella vaccine and their properties. (Lalsiamthara J., et al., 2017)
| Vaccine |
General properties and remarks |
| Live |
1)S19,Rev.1: high levels of protection;residual virulence;zero interference;reports of human infections; not suitable for human use; severe local reactions in actively infected individuals
2) RB51, Knock-out; differentiating infected from vaccinated animals (DIVA); comparatively safe; varying level of protection
|
| Inactive cell lysate |
Highly safe; no residual virulence; low level of protection; requires multiple boosters |
| Subunit |
Highly safe; no residual virulence; low level of protection; requires multiple boosters; DIVA; a cross-protecting platform; suitable for human use |
| DNA |
Highly safe; no residual virulence; low level of protection; requires multiple boosters; requires prime boosting; DIVA; a cross-protecting platform. |
| Synthetic peptide |
Highly safe; highly optimizable; no residual virulence; low level of protection; requires multiple boosters; DIVA; a cross-protecting platform; suitable for human use |
| Live vectored |
Safe; customizable; no residual virulence; DIVA; a cross-protectin platform; varying level of protection; suitable for human use |
Therapeutics Development for Brucellosis
Exploration of disease causing pathogens continues to be a pertinent area of research. The brucellosis causes blindness in due to its ability to liquify cells. One of the strategies in combating Brucella infections, for example in drug resistant or chronic cases, is the use of multi drug therapies. Only time can reveal the exact combination of antibiotics needed to eliminate the pathogen. It is equally critical to find host-directed therapies which enhance the immune system.
In addition to boosting immunity the immune enhancing drugs can be delivered more effectively by using nanoparticles or liposomal agents. This would help combine therapeutics drugs with antimicrobial agents targeting a Brucella infection more directly aiding in the treatment of brucellosis. Underneath is our single point Brucellosis therapeutics. Follow the link to learn more.
Our Services
At our company, we are committed to advancing the field of brucellosis research and leveraging our expertise to support the development of innovative vaccines and therapies. Our team of experienced scientists and researchers specializes in various aspects of brucellosis research, from an in-depth understanding of Brucella biology to the design and evaluation of novel vaccine and therapeutic candidates.
Infectious Disease Models
- Intraperitoneal Infection Models
- Digestive Route Infection Models
- Nasal (Aerosol) Infection Models
- Reproductive Tract Pathogenesis Models
Taking advantage of our professional experience and modern equipment, we offer tailor-made services to our clients. Should our services arouse your interest, please do not hesitate to contact us in order to obtain more comprehensive information about them as well as for an extensive quote on the specific services required.
References
- Yagupsky Pablo, Pilar Morata, and Juan D. Colmenero. "Laboratory diagnosis of human brucellosis." Clinical microbiology reviews 33.1 (2019): 10-1128.
- Lalsiamthara, Jonathan, and John Hwa Lee. "Development and trial of vaccines against Brucella." Journal of Veterinary Science 18.S1 (2017): 281-290.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
